Parsippany, NJ / November 1, 2012 – Validus Pharmaceuticals together with Wood Creek Capital Management, LLC announced today  the acquisition of the U.S. rights to six well-known product lines from Novartis Pharmaceuticals Corporation (NPC): Lopressor^® (metoprolol tartrate USP) but excluding Lopressor (metoprolol tartrate) Injection, Lopressor^® HCT (metoprolol tartrate USP + hydrochlorothiazide USP), Lotensin^® (benazepril HCl), Lotensin HCT^® (benazepril HCl + hydrochlorothiazide USP), Parlodel^® (bromocriptine mesylate USP) and Methergine^® (methylergonovine maleate).

Wood Creek Capital Management acquired the NPC products on August 29, 2012 through a new company, US Pharmaceuticals Holdings I LLC. Validus Pharmaceuticals will serve as the exclusive manager for the ex-NPC lines. These products present Validus with opportunities to generate sales in several new therapeutic markets and represent a significant growth catalyst for the company.

“The management and marketing of these significant new product lines fulfills a major step in Validus Pharmaceuticals’ strategic plan for continued growth”, commented James Hunter, Validus CEO. “The company’s life-cycle plan had called for the timely expansion of product offerings beyond our successful Central Nervous System and Renal product lines. Adding these Novartis-developed medications immediately enables Validus to serve additional large and growing markets, particularly Cardiovascular Health.”

“The acquisition of U.S. rights to these Novartis Pharmaceuticals Corporation products illustrates our belief in and commitment to the mature branded pharmaceuticals market”, says Brett Hellerman, Wood Creek CEO.  “This is another in a series of successful transactions completed with large pharmaceutical companies that demonstrates we are good deal partners.  We are excited about the potential for our strategy.”

As manufacturing of these products transitions to Validus, the company is working rapidly in order to assure both physicians and patients of a continued product supply under their label. Validus will be communicating directly with distributors and prescribing physicians regarding the availability of all these products.

About Validus Pharmaceuticals

Validus Pharmaceuticals LLC is a Parsippany, New Jersey-based specialty pharmaceutical company focused on the acquisition, reformulation, and marketing of FDA-approved prescription products that satisfy unmet clinical needs.  To fulfill this mission, Validus seeks out and acquires marketed products that have well established safety profiles as well as significant clinical benefits.

For additional information please visit www.validuspharma.com

About Wood Creek Capital Management, LLC

Wood Creek Capital Management is an investment manager at the forefront of private assets investing.  Headquartered in New Haven, CT Wood Creek has $930 million of committed capital under management as of June 30, 2012.  Wood Creek is a leading investor in intangible assets including pharmaceutical brands.

For additional information please visit www.woodcreekcap.com

Contact:

James Hunter, President,
Validus Pharmaceuticals LLC
jhunter@validuspharma.com
973. 265.2777

Josh Weinstein / jwEinstein SM, Inc.
jw@jweinteinsm.com
610.577.5388

PLEASANTON, Calif.–(BUSINESS WIRE)–Validus has joined the pharmaceutical iPad revolution by deploying iRep from Veeva Systems to their US sales teams. The organization, which acquires, reformulates, and markets prescription products relevant to the psychiatry market, had been using a CRM system that ran on PDAs and could not accurately report on all sales activity data. In just five weeks, iRep was deployed to a fully trained staff that reports that the ease of use has them hooked. More importantly, sales reps have reported that walking into a physician’s office with an iPad for information sharing is piquing interest with doctors.

Richard Post, vice president sales and marketing at Validus, stated, “We’re seeing that with iRep running on the iPad, doctors are willing to listen to the message and interact more. In several cases, we’ve even seen that they are more easily opening their doors.”

“It may sound corny, but iRep is doing everything we want it to do and then some.”

Validus’ search for a solution that would accurately report against call activity data, was quick and painless for reps to use, and could operate whether or not there was an available internet connection led them to iRep. The screens on the PDA devices they were previously using were very small, which made it difficult for physicians when signing for samples. iRep is built natively to run on the iPad and takes advantage of the large, high quality display.

“We expect the efficiency of sample ordering to increase,” added Post. “And being able to more easily capture information such as calls per day, reach and frequency, and response to marketing messages will give us the exact information we need to be more effective.” Validus is also using the Closed Loop Marketing (CLM) functionality in iRep to display detail aids electronically.

“The results of the Validus deployment of iRep provide additional proof that the iPad is the right device for today’s pharmaceutical representative,” explained Paul Shawah, vice president of multichannel strategy at Veeva Systems.

“It’s a dream come true,” concluded Post. “It may sound corny, but iRep is doing everything we want it to do and then some.”

About Veeva iRep

iRep is the first integrated Pharma CRM and CLM solution designed for the Apple iPad. Veeva completely redesigned its market leading, cloud-based Pharma CRM application to leverage many strengths of the Apple iPad, such as the ‘instant on’ feature, increased battery life, and improved usability. Built-in closed loop marketing functionality also enables iRep users to leverage the iPad’s renowned beautiful presentation of multimedia content while seamlessly aligning sales and marketing strategies.

About Veeva Systems

Veeva Systems is the leader in cloud-based solutions for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has over 80 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Founded in 2007, Veeva is a privately held company headquartered in the San Francisco Bay Area, with offices in Philadelphia, Barcelona, Beijing, and Shanghai. For more information, visit www.veevasystems.com.

Copyright (c) 2011 Veeva Systems. All rights reserved. Veeva and the Veeva logo are registered trademarks of Veeva Systems. Veeva Systems owns other registered and unregistered trademarks. Other names used herein may be trademarks of their respective owners.

Contacts

Veeva Systems, Inc. Lisa Barbadora, 610-420-3413 pr@veevasystems.com

Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, proudly announces the extension of a $6 million senior facility to Validus Pharmaceuticals LLC.

NEW YORK–(BUSINESS WIRE)–Square 1 Bank proudly announces the extension of a $6 million senior facility to Validus Pharmaceuticals LLC, a specialty pharmaceutical company focused on the acquisition and commercialization of effective branded and underutilized products in specialty therapeutic areas. Based in Parsippany, NJ, Validus’ product portfolio currently consists of Marplan®, Equetro®, and Rocaltrol®.
“We were impressed with Square 1′s commitment to the relationship,” stated Validus’ CEO, James Hunter. “They truly understood our unique position in the marketplace and provided the flexibility needed for our company’s growth needs.”

“Validus has a strong platform in place with a great leadership team. We are thrilled to partner with a company that is equally as dedicated to innovation and growth as Square 1,” said Dan Lee, SVP and Managing Director of Square 1′s Growth Finance group.

“Validus has a strong platform in place with a great leadership team. We are thrilled to partner with a company that is equally as dedicated to innovation and growth as Square 1″

About Validus Pharmaceuticals

Validus Pharmaceuticals is a specialty pharmaceutical company founded in Parsippany, NJ, in 2007 to serve the unmet needs of patients in specialty therapeutic areas. The company pursues this mission with targeted and focused marketing efforts and active acquisition and in-licensing programs aimed at underutilized specialty products that have important future potential. Please log-on to www.validuspharma.com for additional information.

About Square 1

Square 1 Bank is a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion. Square 1′s expertise, focus and strong capital base provide solid support for its clients’ needs. The bank offers tailored products and solutions aided by the latest in technological innovations. To serve its relationships, Square 1 has offices coast to coast in Austin, Boston, Boulder, Durham, McLean, New York, San Diego, Santa Monica, Seattle, and Silicon Valley. For more information, visit www.square1bank.com.

Contacts

Square 1 Bank Kristin Beyer, 919-314-3126 AVP, Marketing + Communications kbeyer@square1bank.com

Rocaltrol^® is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, and in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. Rocaltrol^® is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypo-parathyroidism.

“Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorized generic version of Rocaltrol^®. This product represents an excellent commercial opportunity for Ranbaxy which will increase our visibility and presence in the U.S. healthcare system. We look forward to a long and prosperous partnership with Validus,” said Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy will launch product immediately to all classes of trade in the U.S. market, and expects to be the only generic company offering all forms and strengths of generic Rocaltrol^®.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies”, resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd.

Validus Pharmaceuticals LLC is focused on acquiring, developing and marketing effective, underutilized branded products in specialty therapeutic areas. During the past three years, the company has successfully acquired four products with specific therapeutic advantages that provide a current revenue stream. Validus seeks to acquire drug assets that are approved by the FDA and have well defined and accepted clinical utility relevant to today’s practice of medicine. Validus is a portfolio company of Wood Creek Capital Management, LLC, a registered investment advisor that is focused on alternative investments. For more information about Validus Pharmaceuticals, visit www.validuspharma.com.

About ROCALTROL (calcitriol)

ROCALTROL, available as capsules and as an oral solution, is the most potent metabolite of vitamin D available and is active in regulating the absorption of calcium from the gastrointestinal tract and its utilization in the body. The calcitriol in ROCALTROL is believed to be the active hormone which exerts vitamin D activity in the body. ROCALTROL improves calcium absorption in patients who have severe vitamin D deficiencies commonly associated with CRF, chronic kidney disease (CKD), end-stage renal disease (ESRD) or primary hypothyroidism.

ROCALTROL therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of serum calcium. In order to avoid hypercalcemia and related conditions, the optimal daily dose of ROCALTROL must be carefully determined for each patient. The safety and effectiveness of ROCALTROL in pediatric predialysis patients is based on evidence from adequate and well controlled studies of ROCALTROL in adults with predialysis chronic renal failure and additional supportive data from non-placebo controlled studies in pediatric patients. Specific doses of ROCALTROL are recommended for pediatric predialysis patients. These and other precautions and warnings may be found in the package insert for ROCALTROL.

About Fontus Pharmaceuticals

Fontus Pharmaceuticals, Inc. (“Fontus”) is a specialty pharmaceutical company distinguished by its strategy to acquire and market FDA-approved products used in the fields of nephrology and endocrinology. Fontus focuses on mature products with widely accepted clinical value and brand loyalty. Fontus re-invigorates promotion and in some cases reformulates products to optimize clinical benefit. Fontus is the second new specialty pharmaceutical company to be formed with an investment from the private equity fund, Konanda Pharma Fund I, L.P. For more information, please visit www.fontuspharma.com.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is a private equity fund that founds and invests in portfolio companies that acquire mature prescription drug brands that offer important therapeutic benefits. For more information, please visit www.konanda.com.

SOURCE: Fontus Pharmaceuticals, Inc.

PARSIPPANY, N.J., Sept. 11 /PRNewswire/ — Validus Pharmaceuticals LLC announced today that it has acquired the unique Bipolar Disorder treatment, Equetro® (carbamazepine) extended release capsules, from Shire plc. EQUETRO® is a treatment for the acute manic and mixed episodes associated with Bipolar-1 Disorder — a condition where patients experience extended periods of exaggerated highs in addition to the extended lows commonly associated with Bipolar Disorder. Equetro’s patented advanced drug delivery technology also provides patients with the convenience of twice-daily dosing.

“This is a watershed moment in the commercialization of Validus Pharmaceuticals” stated James Hunter, Validus President & CEO. “Equetro® provides mental health professionals with an important treatment option in the management of Bipolar Disorder. Equetro® also fits well within our growing product portfolio which includes Marplan® (isocarboxazid), the classic MAO- inhibitor for treatment-resistant depression.”

Validus Pharmaceuticals will begin active promotion of Equetro® during the U.S. Psychiatric & Mental Health Congress — one of the nation’s largest gatherings of mental health professionals — in Orlando, FL in early October.

About Validus Pharmaceuticals:

Validus Pharmaceuticals is a specialty pharmaceutical company founded in Parsippany, NJ in 2007 to serve the unmet needs of patients with central nervous system (CNS) diseases. The company pursues this mission with targeted and focused marketing efforts and active acquisition and in-licensing programs aimed at underutilized CNS products that have important future potential. Validus is a portfolio company of the Konanda Pharma Fund I, L.P. in New York City. Please log- on to http://www.validuspharma.com for additional information.

About Marplan®

Please go to the Marplan® website http://www.marplan.com for Full Prescribing Information, including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-inhibitors are contraindicated with certain drugs, and potential hypertensive crises may occur with tyramine containing foods. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially within the first few months of therapy.

About Equetro®

Please see complete Prescribing Information for Equetro at http://www.equetro.com. EQUETRO® contains carbamazepine. If you are currently taking another medication that contains carbamazepine, do not begin taking Equetro® without discussing this with your healthcare provider. Products that contain carbamazepine have been associated with rare but serious types of blood disorders. People with Bipolar Disorder have an increased risk for suicide. It is important to discuss risk factors for suicide with your healthcare provider.
About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is an investment fund that is managed by Konanda Pharma Partners, LLC, based in New York City. The Fund acquires mature branded drugs through portfolio companies which it owns and operates. Please log- on to http://www.konanda.com for additional information.

Source: Validus Pharmaceuticals LLC

PARSIPPANY, N.J., May 14 /PRNewswire/ — Validus Pharmaceuticals LLC has acquired Marplan® (isocarboxazid) from Oxford Pharmaceuticals. Marplan® is a highly effective MAOI drug for patients who suffer the enduring and debilitating symptoms of depression and have not responded to other antidepressant drugs. Marplan® works differently than commonly-known ‘SSRI drugs’ because it directly blocks the action of an enzyme called monoamine oxidase. Marplan®, which was first introduced by Roche Pharmaceuticals in the early 1960′s, has an established history of safety and efficacy. Validus has acquired Marplan® and will keep this important antidepressant available on the market for the thousands of patients and doctors who rely on its efficacy to control difficult-to-treat depression.

Physicians have turned to Marplan® therapy when early treatments with SSRIs and other antidepressant drugs failed to control their patients’ severe symptoms of depression and also as a safe and effective alternative treatment prior to electro- convulsive therapy.

“Marplan® is an antidepressant with a distinguished track-record in a very difficult-to-treat patient population,” said James Hunter, Validus Pharmaceuticals’ President and CEO. “Its widely recognized efficacy and safety provide the ideal platform for our entry into the psychiatric marketplace,” he added. Validus plans to begin promoting Marplan® tablets with a portfolio of customer care services for consumers and health professionals at the American Psychiatric Association Meeting beginning May 19, 2007 in San Diego.

About Validus Pharmaceuticals

Validus Pharmaceuticals is a full service pharmaceutical company, based in Parsippany, NJ. Validus is a portfolio investment of Konanda Pharma Partners, a private equity firm in New York City. Validus’ business plan calls for the marketing and support of Marplan® as well as the acquisition and marketing of additional new or underutilized products that have important future potential in the treatment of central nervous system diseases. Please log on to the Validus / Marplan® website http://www.marplan.com for additional information.

About Konanda Pharma Partners

Validus Pharmaceuticals LLC is a portfolio investment of Konanda Pharma Partners, an investment fund focused on acquiring mature branded drugs and building portfolio companies around such products. See http://www.konanda.com for additional information about the Fund’s principals and investment objectives.

Please go to the Marplan website http://www.marplan.com for Full Prescribing Information, including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-inhibitors are contraindicated with certain drugs, and potential hypertensive crises may occur with tyramine containing foods. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of therapy.

Source: Validus Pharmaceuticals LLC